First Tracks Biotherapeutics's EBIT is $-170M, below the Healthcare sector average of $1.1T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
First Tracks Biotherapeutics posts a EBIT of $-170M as of September 2026. That is below the Healthcare sector average of $1.1T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a EBIT near $1.1T is typical. First Tracks Biotherapeutics's $-170M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
EBIT is one piece of First Tracks Biotherapeutics's financial statement story. At $-170M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for TRAX's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $1.1T), and (3) consistency with growth and profitability. This page covers the first two; First Tracks Biotherapeutics's other metric pages and overview cover the third.
Judging First Tracks Biotherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in EBIT easier to interpret. Start with $-170M here, then scan peer and history charts to see if the gap is persistent.